DNA from nine hemophilia B patients who produce anti-factor IX inhibitors (antibodies), including two brothers, was analyzed by the Southern blotting method and hybridization with factor IX cDNA, intragenomic, and 3'-flanking probes. Two inhibitor patients were shown to have total deletions of the factor IX gene. Two other inhibitor patients, the brothers, were shown to have a presumably identical complex rearrangement of the factor IX gene involving two separate deletions. The first deletion is of -5.0 kb and removes exon e. The second deletion is between 9 and 29 kb and removes exons g and h but leaves exon f intact. An abnormal Taq I fragment at one end of the deletion junctions acted as a marker for the inheritence of hemophilia B in the patients' family. Five other inhibitor patients have a structurally intact factor IX gene as detected by this method. Our studies indicate that whereas large structural factor IX gene defects predispose hemophilia B patients to developing an anti-factor IX inhibitor, the development of an inhibitor can be associated with other defects of the factor IX gene.
Introduction
Hemophilia B is an X-linked heterogeneous bleeding disorder in which normal intrinsic clotting factor IX is absent, deficient, or has been replaced by a functionally abnormal factor IX protein.
The disorder affects -1 in 30,000 newborn males in the United Kingdom. Hemophilia B patients receive replacement therapy with factor IX concentrated from pooled normal plasmas. The development of specific anti-factor IX inhibitors (antibodies) occurs in -1% of hemophilia B patients as a consequence of this treatment. Those patients who do not produce any immunologically recognizable factor IX protein are thought to be at most risk of developing an inhibitor to factor IX.
Cloning and sequencing ofthe factor IX gene (1) (2) (3) (4) (5) has made possible the investigation of the factor IX genes of hemophilia B patients. We have also used probes originating from flanking sequences - 25, 40 , and 80 kb 3' to the factor IX gene that have been isolated by gene walking experiments (D. S. Anson and G. G. Brownlee, personal communication). Previous studies have indicated that the majority of noninhibitor patients possess no large structural alterations in the factor IX gene (6) (7) (8) (9) (10) (11) (12) although Chen (13) has reported one noninhibitor patient, Hemophilia B (Seattle 1), with a partial deletion of 10 kb including exons e Patients. Peripheral blood samples were collected on nine hemophilia B inhibitor patients and their family members from Hemophilia Centres in the United Kingdom, United States, France, Japan, Holland, Sweden, and Eire. We have called them Hemophilia B (Jersey 1), (15) , (Boston 1) , (Chicago 1), (Paris 1), (Nara 1), (Bilthoven 1), (Malmo 1), and (Dublin 1). None of the inhibitor patients showed measurable factor IX antigen in their plasma, as measured by immunoelectrophoresis and enzymelinked immunosorbent assay (16) , with a sensitivity of 0.01 U/ml (i.e., 1% of normal plasma levels).
Probes. The factor IX cDNA clone used, cVII, is -2 kb and covers the signal peptide and mature protein coding regions and half the 3' noncoding region of factor IX mRNA ( Fig. 1 ) (4). The intragenic probes XI, VIII, II, and III are located at exons a, d, e, and f respectively of the factor IX gene, and the intragenic probe IV is located midway within the intron between exons f and g ( Fig. 1) inhibitor patients, DNA samples from all three together with a normal male DNA were digested with PvuII and probed with intragenomic probe XI, which includes exon a ( Fig. 1) . A normal fragment of 6.0 kb was generated in each of the patient and control DNAs (tracks 5-8, Fig. 2 Table I and Fig. 5) . Fig. 5 , track 3 contains DNA from a normal male and shows the normal 4.4 and 8.0-kb fragments generated after PvuII digestion and probing with probe VIII (includes exon d, Figs. 1 and 6) . B.K. however shows the normal 4.4-kb fragment together with an abnormal 3.0-kb fragment (Fig. 5, track 4) . Fig. 5 , track 5 shows the normal 3.6 and 1.0-kb TaqI fragments in DNA from a normal male probed with probe II (includes exon e, Figs. 1 and 6) . No autoradiographic signal was observed in DNA from B.K. with this probe, (Fig. 5, track 6 ), implying that this part of the gene is deleted. In contrast DNA from B.K. shows a normal 1.0-kb PvuII fragment (Fig. 5, track 10 ) and an abnormal 4.5-kb TaqI Fig. 6 ). Breakpoint C must be located within the 3 kb immediately 3' to exon f (Fig.  6 ). Breakpoint D must be situated in the 20 kb that separates exon h and the locus for the Eco 3.2 3' flanking probe (Fig. 1) . Breakpoints C and D have generated deletion 2 of between 9 and 29 kb that includes exons g and h. We have also performed a study using TaqI and probe III on this Hemophilia B (Chicago 1) family (Fig. 7) . The patients' grandmother, M.K. (track 4), is homozygous for the normal 3.6-kb fragment, whereas the patients' mother (R.K.) and sister (T.K.), (tracks 2 and 3 respectively) possess the 3.6-kb fragment and the abnormal 4.5-kb fragment. Since the patients' grandfather did not have hemophilia B the mutation must have arisen at the level ofthe patients' mother. An abnormal 11-kb fragment seen after BgIII digestion with probes VIII and/or III (Table I and Fig. 6 ) in B.K. and P.K. and their mother R.K. is a marker for the presence of both deletions (results not shown). Interestingly, since grandmother M.K. only shows the normal 12-kb BglII fragment with probe III, then both deletions appear to have arisen at the same time.
In addition DNA from 25 noninhibitor hemophilia B patients was digested independently with 15 different restriction enzymes and probed with the cDNA probe. In each case all the hybridization fiagments were found to be normal (results not shown).
Discussion
Of the nine hemophilia B inhibitor patients studied, including two brothers, five appear to have intact factor IX genes. We presume that gene mutations such as single nucleotide changes or small deletions rarely detected by this kind of analysis are responsible for the defect in these patients. A single nucleotide substitution affecting the correct maturation of factor IX mRNA has already been described in one case of severe hemophilia B (24) . Fig. 8 illustrates the extent of the deletions in Hemophilia B (Jersey 1), (Boston 1), and (Chicago 1) compared to factor IX deletions already reported (6, 8, 13, 14) .
The deletions in Hemophilia B (Jersey 1) and (Boston 1) are ofa minimum size of 1 14 kb, but the 5' and 3' breakpoints have yet to be characterized. The factor IX gene has been located to the Xq27 region of the X-chromosome (25) (26) (27) (28) . Since Hemophilia B (Jersey 1) and (Boston 1) show a positive result with pX45h, also located in the Xq27 region (17, 18) , at least one of the deletion breakpoints in these conditions must be situated within this region. Karyotype analysis in Hemophilia B (Jersey (6, 8, 13, 14) . (30) . In this condition all the correct signals for 3' processing of the factor IX mRNA are presumed to be intact allowing a truncated factor IX protein to be translated.
It is interesting to note that the 5' breakpoints in Hemophilia B (Chicago 1) (deletion 2) and (London 1), (a partial deletion reported by Giannelli et al., reference 6), and the 3' breakpoints in Hemophilia B (Chicago 1) (deletion 1), (Seattle 1) (13), and (Bari 1) (14) , are located near Alu repeat sequences. Four highly repetitive Alul sequences are present in the factor IX gene (5) . The first is in the intron between exons a and b, and the next three are within the intron between exons f and g. A fifth is found in the flanking region of the 3' end of the gene. Reports that some f3-globin gene cluster (31, 32) and low-density lipoprotein receptor gene (33) deletions have breakpoints close to or within family repeat sequences possibly indicates the existence of a general mechanism that can result in large gene deletions. It is hoped that by cloning and sequencing the deletion junction regions of Hemophilia B (Chicago 1) the proximity of the repeat sequences will be better assessed.
Giannelli et al. (6, 34) have proposed that the origin of antibodies to factor IX in hemophilia B patients is due to their lack of immune tolerance to epitopes in the factor IX protein. This can either be due to lack of expression of any factor IX antigen, or to synthesis of an altered factor IX molecule lacking certain epitopes that are critical for the initial development of tolerance. Whereas all nine hemophila B patients we have studied appear to satisfy these criteria in having undetectable plasma factor IX, in only four is this absence due to a large deletion of the factor IX gene. In addition several ofthe noninhibitor patients we have studied do not produce any measurable factor IX antigen in plasma. However it is possible that these patients synthesize small amounts of factor IX that, although undetectable by our assays, are sufficient to allow induction of immune tolerance. Alternatively these patients may have lost the ability to synthesize factor IX after the development of tolerance. Secondary factors such as the treatment regime and/or polymorphism of the immune response could also be influential in predisposing only a percentage of hemophilia B patients to develop an inhibitor (35) . Evidence for this comes from family studies where only one of two affected individuals has developed an inhibitor (35) .
Of the 14 hemophilia B inhibitor patients thus far reported, eight have a detectable deletion of the factor IX gene (6, 8, 14, 15 , and this study), whereas in only 2 of 19 hemophilia A inhibitor patients studied is inhibitor development associated with a detected gene deletion (36) (37) (38) (6) (7) (8) (9) (10) (11) (12) (13) (14) (36) (37) (38) , single nucleotide changes or small insertions/deletions in the factor VIII gene appear to result in the development of inhibitors in hemophilia A more frequently than similar kinds of changes in the factor IX gene in hemophilia B. This is presumably due to loss of the epitopes critical to the development of immune tolerance as discussed above. Additionally the much lower plasma level of factor VIII compared with factor IX (-100 ng/ml compared with 10 ,gg/ml) may be significant in the establishing of self-immune tolerance to these proteins in hemophilia A and B patients with lowered levels of factor VIII and factor IX respectively.
